ArticleEULAR rheumatology open2026
Standardised multidisciplinary rehabilitation improves health-related quality of life and productivity costs in patients with rheumatic, musculoskeletal and other diseases.
Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aims to assess changes in health-related quality of life (HRQoL) and productivity costs following rehabilitation. Methods: This prospective cohort study of rheumatic and musculoskeletal diseases (RMDs) and 7 other groups collected HRQoL EuroQol 5-Dimension 5-Level (EQ-5D-5L) data for 12 months and work absence data for 24 months postrehabilitation. Differences from baseline in quality-adjusted life years (QALYs) and productivity costs were estimated using the area-under-the-curve method and human capital approach, respectively. Results were adjusted for age, gender (biologically), and education. Results: We included 3192 patients: mean age 53.1 years, 71% female, 42% had RMDs. HRQoL improved for all participants over 12 months, except for neurological and cancer patients. Differences in QALYs from baseline ranged from -0.014 (neurological diseases) to 0.075 (RMDs). Among 2642 employed participants, productivity costs decreased over 24 months, driven mainly by reduced sick leave (largest in cancer €18,110, smallest in neurological diseases €5747). In contrast, productivity costs for severe obesity increased by €11,614. Mean rehabilitation costs ranged from €3072 to €11,674 for cancer and neurological diseases, respectively, and were €7923 for RMDs. Conclusions: Following rehabilitation, participants improved in HRQoL and reduced productivity costs from baseline, driven mainly by lower sick leave. Randomised controlled trials are needed to confirm the extent to which these improvements are attributable to the rehabilitation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.